David Nierengarten
Stock Analyst at Wedbush
(4.42)
# 311
Out of 5,152 analysts
215
Total ratings
53.98%
Success rate
18.38%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TCRX TScan Therapeutics | Maintains: Outperform | $4 → $5 | $1.08 | +362.96% | 5 | Mar 5, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $90 → $95 | $72.31 | +31.38% | 4 | Mar 3, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 → $65 | $27.44 | +136.88% | 4 | Feb 25, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $50 → $53 | $47.27 | +12.12% | 6 | Feb 25, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $13.51 | +48.04% | 10 | Feb 24, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Underperform | $110 | $116.77 | -5.80% | 1 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Outperform | $110 → $88 | $61.10 | +44.03% | 5 | Feb 17, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.74 | +132.07% | 12 | Feb 10, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $5.27 | +108.73% | 5 | Jan 30, 2026 | |
| COGT Cogent Biosciences | Reiterates: Outperform | $55 | $37.02 | +48.57% | 4 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $22.52 | +37.66% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $18 | $13.42 | +34.13% | 9 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $749.56 | +33.41% | 24 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $18.54 | +61.81% | 3 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $10.17 | +145.82% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $13.82 | -49.35% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.45 | +382.76% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $102.67 | +12.01% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4 | $4.73 | -15.43% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $12.74 | +104.08% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $6.87 | +220.23% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $15.05 | -46.84% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $21.31 | -6.15% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $60.55 | -33.94% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $47.43 | -0.91% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $34.99 | +14.32% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $41.00 | +9.76% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.46 | +229.67% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.12 | +191.26% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.28 | +21,829.82% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $9.15 | +555.74% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.20 | +131.71% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $21.80 | +244.04% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.13 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.86 | - | 3 | Nov 20, 2017 |
TScan Therapeutics
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.08
Upside: +362.96%
Apogee Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $72.31
Upside: +31.38%
Beam Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $27.44
Upside: +136.88%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Outperform
Price Target: $50 → $53
Current: $47.27
Upside: +12.12%
ORIC Pharmaceuticals
Feb 24, 2026
Reiterates: Outperform
Price Target: $20
Current: $13.51
Upside: +48.04%
ABIVAX Société Anonyme
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $116.77
Upside: -5.80%
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $61.10
Upside: +44.03%
Nuvation Bio
Feb 10, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.74
Upside: +132.07%
Perspective Therapeutics
Jan 30, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.27
Upside: +108.73%
Cogent Biosciences
Jan 21, 2026
Reiterates: Outperform
Price Target: $55
Current: $37.02
Upside: +48.57%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $22.52
Upside: +37.66%
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $13.42
Upside: +34.13%
Jan 14, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $749.56
Upside: +33.41%
Jan 13, 2026
Reiterates: Outperform
Price Target: $30
Current: $18.54
Upside: +61.81%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $10.17
Upside: +145.82%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $13.82
Upside: -49.35%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.45
Upside: +382.76%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $102.67
Upside: +12.01%
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $4.73
Upside: -15.43%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.74
Upside: +104.08%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $6.87
Upside: +220.23%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $15.05
Upside: -46.84%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $21.31
Upside: -6.15%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $60.55
Upside: -33.94%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $47.43
Upside: -0.91%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $34.99
Upside: +14.32%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $41.00
Upside: +9.76%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $5.46
Upside: +229.67%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.12
Upside: +191.26%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.28
Upside: +21,829.82%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $9.15
Upside: +555.74%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.20
Upside: +131.71%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $21.80
Upside: +244.04%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.13
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.86
Upside: -